AstraZeneca Investor Day Presentation Deck

Patient disposition 10 Randomised to T-DXd (n = 261) Treated (n = 257) Ongoing study treatment (n = 132) Discontinued study treatment (n = 125) Death (n = 3) Adverse event (n = 35) Progressive disease (n = 66) ● ● ● ● ● ● Screened (n = 699) Clinical progression (n = 4) Withdrawal by subject (n = 13) Physician decision (n = 2) Other (n = 2) Randomised (n = 524) Randomised to T-DM1 (n = 263) Treated (n = 261) Ongoing study treatment (n = 47) Discontinued study treatment (n = 214) Death (n = 3) Adverse event (n = 17) Progressive disease (n = 158) ● ● ● ● ● Clinical progression (n = 12) Withdrawal by subject (n = 11) Physician decision (n = 8) Other (n = 5) Median follow up for T-DXd was 16.2 months and for T-DM1 was 15.3 months ● ●

View entire presentation